Articles tagged "T cells"

2018 American Transplant Congress
Assessment of Immune Cell Profiles in HLA-Sensitized (HS) & Non-HS Patients (Pts) with End Stage Renal Disease (ESRD)
S. Ge,¹ M. Chu,¹ E. Ortiz,¹ A. Vo,² D. Lovato,¹ S. Jordan,² M. Toyoda.¹
¹Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA; ²Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Background: Chronic inflammation is often seen in pts w/ ESRD. HLA-sensitization may create or be driven by the cytokines responsible for chronic inflammation. Here we…
2018 American Transplant Congress
Involvement of PD-L1 Upregulation in Anti-A/B Antibody-Induced Graft Accommodation: Reduction of CD4 T Cell Allo-Response against Graft HLA Class II DR
K. Iwasaki,¹ Y. Miwa,¹ H. Hamana,³ H. Kishi,³ A. Muraguchi,³ K. Uchida,¹ T. Kobayashi.²
¹Kidney Disease and Transplant Immunology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan; ²Renal Transplant Surgery, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan; ³Immunology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
[Background] Antibodies against transplanted organs cause complement-independent graft injury, but there remain many unknown aspects of its mechanism, in particular its effect on allo-response to…
2018 American Transplant Congress
Type I NKT Cells Augment Humoral and Cellular Alloimmunity in Response to Hepatocyte Transplantation
S. Elzein, J. Zimmerer, B. Ringwald, C. Avila, G. Bumgardner.
Surgery, The Ohio State University Wexner Medical Center, Columbus, OH.
Hepatocyte transplantation (HcTx) is a potential therapeutic modality for patients with liver disease. Despite examples of antigen acceptance in the liver, allogeneic HcTx into patients…
2018 American Transplant Congress
An Individualized Strategy Using Virus and Immune-Based Markers to Prevent Cytomegalovirus Disease after Face Transplantation
R. Razonable, H. Amer, S. Mardini.
Mayo Clinic, Rochester, MN.
Introduction: There is limited data on CMV prevention after face transplantation. We report an individualized approach using prophylaxis followed by surveillance and preemptive therapy guided…
2018 American Transplant Congress
What's Normal? An Evaluation of Pediatric T Cell Markers in Healthy Controls
M. Sosniuk,¹ A. Halpin,^1,2,5,6,7 J. Wizniak,⁷ A. Szkotak,^6,7 S. Urschel,^1,2,5 L. Ionescu,^1,2,5 L. West.^1,2,3,4,5,6
¹Dept of Pediatrics, U of Alberta, Edmonton, Canada; ²Alberta Transplant Institute, Edmonton, Canada; ³Dept of MMI, U of Alberta, Edmonton, Canada; ⁴Dept of Surgery, U of Alberta, Edmonton, Canada; ⁵Canadian National Transplant Research Program, National, Canada; ⁶Dept of Laboratory Medicine, U of Alberta, Edmonton, Canada; ⁷Laboratory Medicine and Pathology, Alberta Health Services, Edmonton, Canada.
INTRODUCTION: Studying pediatric patients includes challenges such as difficulty obtaining samples, limited normal controls and small volumes. Standardized flow cytometry (FC) lymphocyte immunophenotyping panels are…
2018 American Transplant Congress
Lymphocyte Proportions Post Thymectomy Are Associated with Allergic Disorders in Heart Transplanted Children
T. Kim,¹ L. Ionescu,^1,2,3 N. Avdimiretz,⁴ M. Larsen,^1,2,3 F. Murdoch,^1,2 B. Motyka,^1,2,3 S. Gilmour,^1,2 L. West,^1,2,3 S. Urschel.^1,2,3
¹Pediatrics, University of Alberta, Edmonton, AB, Canada; ²Stollery Children's Hospital, Edmonton, AB, Canada; ³Alberta Transplant Institute, Edmonton, Canada; ⁴The Hospital for Sick Children, Toronto, Canada.
Background: Allergic disorders are more common in pediatric heart transplant (HTx) recipients than non-transplanted children, with young age at HTx and thymectomy being risk factors.…
2018 American Transplant Congress
Metabolic Therapy as a Platform for CTLA4Ig Costimulation Blockade in Preventing Allograft Rejection
C-.H. Cheng,^1,2 C-.F. Lee,^1,2 G. Furtmüller,³ B. Oh,³ C. Patel,¹ Y-.C. Lo,¹ M. Fryer,³ G. Brandacher,³ J. Powell.¹
¹Sidney-Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD; ²Department of Liver and Transplantation Surgery, Chang-Gung Memorial Hospital, New Taipei City, Taiwan; ³Vascularized Composite Allotransplantation Laboratory, Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
The backbone of current immunosuppression regimens remains calcineurin inhibitors (CNI) in association with steroids, mycophenolate mofetil or mTOR inhibitors. However, their long-term administration is associated…
2018 American Transplant Congress
Preformed Donor-Reactive T-Cells That Persist after ABO Desensitization Independently Predict Severe Acute Cellular Rejection after Living Donor Kidney Transplantation
T. Schachtner,^1,2,3 M. Stein,² P. Reinke.^1,2
¹Nephrology and Internal Intensive Care, Charite Campus Virchow Clinic, Berlin, Germany; ²Berlin-Brandenburg Center for Regenerative Therapie (BCRT), Charite Campus Virchow Clinic, Berlin, Germany; ³Berlin Institute of Health (BIH), Charite and Max Delbrueck Center, Berlin, Germany.
Donor-reactive T-cells have been suggested to impact allograft outcome due to a higher incidence of acute celluar rejection. These donor-reactive memory T-cells rapidly acquire effector…
2018 American Transplant Congress
Leukocytes from Recipients with Severe Primary Graft Dysfunction after Lung Transplant Adoptively Transfer Alloreactivity to Vessel Grafts Trans Vivo
A-.K. Knoefel,¹ T. Siemeni,¹ N. Madrahimov,¹ W. Sommer,¹ M. Avsar,¹ L. Ahrens,¹ I. Tudorache,¹ A. Haverich,¹ C. Falk,² G. Warnecke.¹
¹HTTG, MHH, Hannover, Germany; ²Transplantimmunology, MHH, Hannover, Germany.
Introduction: Primary graft dysfunction (PGD) is the main cause of early mortality after lung transplantation (LTx). Multiple mechanisms have been described, but the link between…
2018 American Transplant Congress
Tregs Expression Predicts Prognosis in Patients with Hepatocellular Carcinoma
A. Baquerizo,¹ V. Vavinskaya,² C. Frenette,¹ M. Nelson,¹ R. Schaffer,¹ J. Fisher,¹ L. Sher,³ B. Madani,¹ P. Pockros,¹ C. Marsh.¹
¹Surgery / Transplant, Scripps Green Hospital, La Jolla, CA; ²Pathology, UCSD, San Diego, CA; ³Surgery / Transplant, USC, Los Angeles, CA.
New therapeutic strategies are needed to improve the survival of patients with hepatocellular carcinoma (HCC), the third in overall global cancer-related mortality. T regulatory cells…